Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05790213 · ClinicalTrials.gov registry record · Phase 2
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
A Phase 2 study of Prostate Cancer, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT05790213 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 57 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05790213, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).
Conditions Studied
Interventions
- DRUG Androgen Deprivation Therapy (ADT)
- PROCEDURE Focal prostate ablation (focal therapy)
Study Locations (1)
Illinois
- UChicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2028-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05790213
The ClinicalTrials.gov registry entry for NCT05790213 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Androgen Deprivation Therapy (ADT) is the first listed.
NCT05790213 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05790213 about?
NCT05790213 is a clinical study titled "Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation". The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).
What is the current status of trial NCT05790213?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2025-05-05. Estimated completion is 2028-12-18.
What conditions does trial NCT05790213 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05790213?
The interventions under investigation include: Androgen Deprivation Therapy (ADT) (DRUG), Focal prostate ablation (focal therapy) (PROCEDURE).
Who is sponsoring clinical trial NCT05790213?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05790213 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.